Details of the Drug

General Information of Drug (ID: DMTZC5G)

Drug Name
Bezlotoxumab
Synonyms CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava
Indication
Disease Entry ICD 11 Status REF
C. difficile infection 1A04 Approved [1]
Affected Organisms
Peptoclostridium difficile
ATC Code
J06BC03: Bezlotoxumab
J06BC: Antibacterial monoclonal antibodies
J06B: IMMUNOGLOBULINS
J06: IMMUNE SERA AND IMMUNOGLOBULINS
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Monoclonal antibody
ADMET Property
Clearance
The clearance of drug is 0.317 L/day []
Half-life
The concentration or amount of drug in body reduced by one-half in 19 Days [2]
Vd
The volume of distribution (Vd) of drug is 7.33 L []
Cross-matching ID
UNII
4H5YMK1H2E
DrugBank ID
DB13140
TTD ID
D09KRE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Clostridium difficile Toxin B (CD toxB) TTQH65V TOXB_CLODI Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds